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Abstract
Cholinergic as well as monoaminergic neurotransmission seems to be
involved in the etiology of affective disorders. Chronic treatment with
imipramine, a classical antidepressant drug, induces adaptive changes
in monoaminergic neurotransmission. In order to identify possible
changes in cholinergic neurotransmission we measured total, mem-
brane-bound and soluble acetylcholinesterase (Achase) activity in
several rat brain regions after chronic imipramine treatment. Changes
in Achase activity would indicate alterations in acetylcholine (Ach)
availability to bind to its receptors in the synaptic cleft. Male rats were
treated with imipramine (20 mg/kg, ip) for 21 days, once a day.
Twenty-four hours after the last dose the rats were sacrificed and
homogenates from several brain regions were prepared. Membrane-
bound Achase activity (nmol thiocholine formed min-1 mg protein-1)
after chronic imipramine treatment was significantly decreased in the
hippocampus (control = 188.8 ± 19.4, imipramine = 154.4 ± 7.5,
P<0.005) and striatum (control = 850.9 ± 59.6, imipramine = 742.5 ±
34.7, P<0.005). A small increase in total Achase activity was observed
in the medulla oblongata and pons. No changes in enzyme activity
were detected in the thalamus or total cerebral cortex. Since the levels
of Achase seem to be enhanced through the interaction between Ach
and its receptors, a decrease in Achase activity may indicate decreased
Ach release by the nerve endings. Therefore, our data indicate that
cholinergic neurotransmission is decreased after chronic imipramine
treatment which is consistent with the idea of an interaction between
monoaminergic and cholinergic neurotransmission in the antidepres-
sant effect of imipramine.
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Introduction
Cholinergic neurotransmission is involved
in many aspects of central nervous system
function, such as learning and memory (1,2)
and rapid eye movement sleep generation
(3,4). It also seems to be involved in patho-
logical conditions such as Alzheimer’s dis-
ease (2) and depression (5,6).
Imipramine, one of the most extensively
studied tricyclic antidepressants, inhibits 5-
hydroxytryptamine (5-HT) uptake both in
vitro and in vivo and chronic treatment in-
duces adaptive changes in brain monoamin-
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ergic neurotransmission (7-12). Janowsky
et al. (6) proposed that depression in humans
may be associated with overactive cholin-
ergic and decreased monoaminergic neu-
rotransmission. Data in the literature have
shown that imipramine, besides having a
serotonergic action, may also have a cholin-
ergic effect since it binds to the muscarinic
receptor (13,14). Therefore, it seems worth-
while to study the effect of imipramine on
neurotransmitters other than monoamines.
Acetylcholinesterase (Achase, EC
3.1.1.7) is an important constituent of cho-
linergic neurotransmission (15) and hydro-
lyzes acetylcholine (Ach) in the synaptic
cleft, thus terminating its action. The num-
ber of Achase molecules can be up-regulated
(16) or down-regulated (17). Inhibition of
Achase leads to a down-regulation of cholin-
ergic receptors (18,19). The levels of Achase
appear to be controlled by the interaction of
Ach with its receptor, with an enhanced
interaction increasing the levels of Achase
(20). Therefore, Achase can be used as an
index of cholinergic function, and changes
in enzyme activity may indicate alterations
in the availability of Ach at the level of its
receptors.
A few investigators have studied the ef-
fect of antidepressants on Achase activity.
To our knowledge, only Geoffroy et al. (21)
have reported the effect of chronic imipramine
treatment on Achase activity in brain re-
gions. However, these authors assayed the en-
zyme activity in whole homogenates and in
their experimental design added behavioral
manipulations to drug treatment, making it diffi-
cult to interpret their results in terms of the
effect of the drug alone on Achase activity.
In the present study we report a decrease
in the activity of membrane-bound Achase
in the striatum and hippocampus after chronic
imipramine treatment. Our data suggest an
interaction between monoaminergic-cholin-
ergic neurotransmission in the brain which
may be involved in the antidepressant effect
of the drug.
Material and Methods
Subjects
Male Wistar rats, 3 months old, weighing
250-300 g, from our own breeding facilities
were used in the experiment. After weaning,
the rats were kept 3 to a wire cage under
controlled temperature (22oC) and on a 12-h
light-dark cycle (lights on from 7:00 to 19:00
h). The animals had free access to food and
water until sacrifice.
Imipramine hydrochloride (Ciba-Geigy
Co., São Paulo) diluted in distilled water was
administered intraperitoneally, once a day
for 21 days (around 9:00 a.m.), at a dose of
20 mg/kg (0.1 ml/100 g body weight). Con-
trol rats received vehicle. Control and treated
rats were sacrificed 24 h after the last dose.
The dose of imipramine and the time-course
of treatment were chosen on the basis of
available data showing significant changes
in brain neurotransmission.
Tissue preparation
After decapitation, the brains were ex-
cised and kept on a cooled Petri dish on
crushed ice. Brains were washed superfi-
cially with isotonic saline to clear the tissue
of blood. Different brain regions (total cere-
bral cortex, hippocampus, thalamus, stria-
tum, pons and medulla oblongata) were dis-
sected immediately. Tissue was weighed and
kept in cold 0.32 M sucrose buffered with
Tris to pH 7.4.
Homogenate preparation
Homogenates (5% w/v) were prepared in
ice-cold 0.32 M sucrose using glass homog-
enizer tubes and a motor-driven TeflonTM
pestle and tissue fractions were prepared
according to Chubb and Smith (22). Homo-
genates were centrifuged at 900 g for 10 min
at 0oC. The supernatant was collected and
centrifuged at 100,000 g for 60 min at 4oC.
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The resulting supernatant was the source of
soluble Achase and the resulting pellet was
resuspended in the original volume. This
latter preparation was the source for mem-
brane-bound Achase. Enzyme activity was
also measured in the 900 g supernatant. Ho-
mogenates were kept at -20oC until assayed.
Determination of Achase activity
Achase activity was determined using
the method of Ellman et al. (23) modified for
microassays. Acetylthiocholine was used as
substrate at a final assay concentration of 1
mM. All materials, including reagents and
homogenates, were kept on crushed ice be-
fore incubation. Enzyme activity was deter-
mined in duplicate for both samples and
blanks. One hundred µl of buffer-substrate
(0.1 M sodium phosphate buffer, pH 8, plus
acetylthiocholine iodide) was pipetted into a
microtube and 5 µl of the homogenate  was
added. Blanks were obtained by adding 15
µl of 2.4 N perchloric acid to the tubes
before incubation. The tubes were incubated
for 30 min in a shaking water bath at 37oC.
After the addition of perchloric acid the
enzyme activity tubes were centrifuged at
2,250 g for 15 min at 0oC. An aliquot of 50 µl
was pipetted into another tube and 500 µl of
Ellman’s reagent was added. After standing
for 15 min at room temperature, samples
were read in a Beckman DU-2 spectropho-
tometer using microcuvettes at 412 nm. Pro-
teins were assayed by the method of Lowry
et al. (24) using bovine serum albumin as
standard.
The activity of Achase is reported as
nmol thiocholine formed min-1 mg protein-1.
The assay was set up to allow the reaction to
be linear for both tissue concentration and
incubation time. To test for the contribution
of butyrylcholinesterase to the hydrolysis of
Ach, the enzyme activity was measured us-
ing butyrylthiocholine as the substrate at 1
mM final concentration. Since the activity
was very low (<5%), as also shown by others
(25), no inhibitor of butyrylcholinesterase
was used.
Reagents
All reagents used were from Sigma Chem-
ical Co. (St. Louis, MO) and were analytical
grade. Twice-distilled water prepared with
an all-glass apparatus was used throughout
the assays.
Statistical analysis
The Student t-test was used to test for
statistical differences (P≤0.05, two-tailed).
Results
The data in Table 1 show that chronic
imipramine treatment induced a highly sig-
nificant decrease in Achase activity in the
hippocampus in the 900 g supernatant frac-
tion (t = 3.04, df = 10, P<0.02) and in the
100,000 g pellet (t = 4.04, df = 10, P<0.005)
but no change was observed in the 100,000 g
supernatant. A highly significant decrease in
Achase activity (Table 1) was also observed
in the striatum after chronic imipramine in
both the 900 g supernatant (t = 4.63, df = 10,
P<0.001) and 100,000 g pellet (t = 3.87, df =
10, P<0.005). No difference was observed in
Table 1 - Achase activity in the hippocampus and striatum of rats chronically treated
with imipramine.
Achase activity is reported as nmol thiocholine formed min-1 mg protein-1. Results are
reported as mean – SD for 6 animals in each group. Final acetylthiocholine concentra-
tion in the assay was 1 mM. *P<0.02, **P<0.005, ***P<0.001 compared to control
(Student t-test).
Brain region Supernatant Pellet Supernatant
900 g 100,000 g 100,000 g
Hippocampus
Control 141.2 – 18.3 188.8 – 19.4 101.6 – 15.0
Imipramine 112.0 – 14.6* 154.4 – 7.5** 92.0 – 12.5
Striatum
Control 659.9 – 28.9 850.9 – 59.6 305.6 – 23.1
Imipramine 581.5 – 29.8*** 742.5 – 34.7** 274.8 – 46.0
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the 100,000 g supernatant.
Chronic imipramine treatment induced a
small but significant increase in Achase ac-
tivity in the medulla oblongata only in the
900 g supernatant fraction (control = 143.3 ±
8.2, imipramine = 157.6 ± 8.0; t = 3.04, df =
10, P<0.02). There was no statistically sig-
nificant difference between the 100,000 g
pellet and the supernatant. In the pons, a
small but statistically significant increase
was also observed only in the 900 g superna-
tant (control = 200.6 ± 7.9, imipramine =
213.3 ± 6.9; t = 2.90, df = 10, P<0.02) (data
not shown). No statistically significant dif-
ferences in Achase activity after chronic
imipramine were observed for the thalamus
or total cerebral cortex in any of the fractions
assayed (data not shown).
Discussion
The main finding of the present study
was a significant decrease in membrane-
bound Achase activity in the hippocampus
and striatum after chronic imipramine treat-
ment. Although we also observed statisti-
cally significant differences in other brain
regions (medulla oblongata and pons), they
were obtained only in the total fraction (900
g) and were small in amplitude. Therefore,
from a biological point of view, they may
have no great significance for the effect of
the drug.
The decrease in Achase activity may lead
to changes in cholinergic receptors after
chronic imipramine treatment. Data in the
literature have shown that chronic imipramine
treatment did not change the number of mus-
carinic receptors in the striatum (8,26) or
hippocampus (26). However, there is a re-
port showing an increased number of recep-
tors in the striatum (27). Due to the known
diversity of both muscarinic and nicotinic
brain cholinergic receptors (28,29) the pos-
sibility of a change in these receptors cannot
be ruled out.
The decrease in Achase activity in the
striatum and hippocampus after chronic imi-
pramine treatment may indicate a secondary
change induced by the drug acting primarily
on serotonergic synapses through serotoner-
gic afferents to these regions. Cholinergic
neurons in the striatum are mostly intrinsic
to this brain region and afferent connections
from serotonergic raphe nuclei to the stria-
tum have been described (30). Cholinergic
projections to the hippocampus through the
fornix arise in basal forebrain neurons and
the hippocampus also receives projections
from serotonergic raphe nuclei (30). These
anatomical data seem to favor an indirect
action of imipramine on cholinergic neu-
rotransmission.
The striatum is one of the richest cholin-
ergic areas in the brain and all cholinergic
markers are highly concentrated in this brain
region (31,32). The striatum is involved in
the control of motor behaviors but its in-
volvement with affective behavior has not
yet been described, although Graybiel (33)
has raised this possibility. Therefore, the
effect of imipramine on this brain region
may be involved in its antidepressant effect.
Cholinergic neurons in the striatum are un-
der dopaminergic afferent control and chronic
imipramine treatment has been shown to
induce a decrease in D1 dopaminergic recep-
tors (8,11) and in Bmax of [3H]DTG binding
to the haloperidol-sensitive sigma sites (34).
On the other hand, imipramine binds with
high affinity to striatum membranes and this
site seems to be located on the 5-HT trans-
porter (35). Moreover, imipramine decreases
[3H]5-HT binding to striatal membranes (9).
These data support the view that the effect of
imipramine on Achase activity is not a direct
one.
Chronic imipramine has been shown to
induce several effects in the hippocampus,
including sensitization of hippocampal CA1
neurons to the inhibitory effect of 5-HT (36),
potentiation of the increase in the neuronal
firing rate induced by a D2 dopaminergic
agonist (37), an increase of the suppressant
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effect of the electrical stimulation of the
afferent 5-HT pathway on the firing activity
of CA3 pyramidal neurons (38), a decrease
in 5-HT2 receptor sites (7), a decrease in 5-
HT and beta-adrenergic receptor sites (9), a
decrease in 5-HT transporter sites (12), and a
reduction of inhibition of forskolin-stimulat-
ed adenylate cyclase by 5-HT (10). These
data indicate that, as observed in the stria-
tum, the changes in Achase activity observed
after chronic imipramine may also reflect
alterations induced by the drug primarily on
serotonergic neurotransmission. The hippo-
campus is a brain structure involved in emo-
tions, being part of the limbic system (39),
and changes in hippocampal cholinergic neu-
rotransmission induced by chronic imi-
pramine may be involved in the antidepres-
sant effect of the drug.
Recent data in the literature using micro-
dialysis techniques have shown an interac-
tion between brain serotonergic and cholin-
ergic neurotransmission. Drugs enhancing
serotonergic neurotransmission when admin-
istered acutely increase the release of Ach in
vivo in the hippocampus (40). We did not
find data in the literature on the release of
Ach after chronic imipramine treatment
which could help establish a relationship
between the decrease in Achase activity and
Ach levels in the hippocampus.
The indirect effect of imipramine on cho-
linergic neurons suggested by our results
may also involve its metabolite desipramine
which is an antidepressant drug that inhibits
the uptake of noradrenaline. Therefore, the
changes in Achase activity may also involve
noradrenergic neurotransmission.
In conclusion, our results show that
chronic imipramine treatment changes mem-
brane-bound Achase activity only in some
brain regions, probably leading to a change
in cholinergic neurotransmission. Our data
obtained in rats seem to support Janowsky’s
proposal (6) of an involvement of cholin-
ergic neurotransmission in human depres-
sion.
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